08:09 AM EDT, 07/23/2024 (MT Newswires) -- Kiniksa Pharmaceuticals ( KNSA ) reported Tuesday that it swung to a Q2 loss of $0.06 per share from earnings of $0.21 a year earlier.

Three analysts polled by Capital IQ expected earnings of $0.01 per share.

Revenue for the quarter ended June 30 was $108.6 million, compared with $71.5 million a year earlier.

Five analysts surveyed by Capital IQ expected $91.3 million.

The company raised its 2024 net product revenue of Arcalyst to now be between $405 million and $415 million, compared with prior guidance of between $370 million and $390 million.

Price: 22.42, Change: +1.03, Percent Change: +4.82